What Fareston Treats: Main Uses and Benefits

Fareston is prescribed for the palliative treatment of metastatic breast cancer in postmenopausal women. This medication is commonly used across conditions presenting with advanced hormone-dependent tumor growth that is classified as estrogen receptor-positive (ER+). The primary indications are therefore managing advanced hormone-sensitive malignancy and addressing related estrogen-driven symptom clusters.

The therapeutic benefit to the patient is the ability to influence disease course by slowing down or helping to limit the progression of these tumors, which may help limit the physical impact of the cancer spreading. As an established part of hormonal therapy, it is applied across domains where additional symptomatic support is needed. It may also assist with managing hormone-related discomfort and is commonly used to help with easing the burden of breast pain, or mastalgia, when symptoms interfere with daily comfort.

“This application assists with maintaining functional stability and supports the patient during difficult episodes by contributing to easing the overall symptom load associated with disease advancement.”

---

Quick Fact: Relief for Advanced Disease Burden

Use Category	Common Scenario	Patient Benefit
Therapeutic Role	Palliative Endocrine Therapy	Used for managing advanced disease
Symptom Focus	Hormone-Related Discomfort	May assist with discomfort
Context	ER+ Metastatic Disease	Provides supportive role in management

---

Regulatory References

1. Fareston | European Medicines Agency (EMA)

The official regulatory documentation for Fareston (Toremifene) establishes strict population criteria, defining who is eligible to use the medicine and who is absolutely prohibited from use.

Eligibility Scope

Classification	Rule (As Stated in Label)
Allowed Population	Postmenopausal women with Estrogen Receptor-Positive (ER+) metastatic breast cancer.
Contraindicated	Patients with Congenital or Documented Acquired QT Prolongation (Long QT Syndrome), Uncorrected Hypokalemia, or Uncorrected Hypomagnesemia [FDA Label].
Contraindicated	Patients with known Hypersensitivity to the drug or severe Hepatic Failure (for long-term use) [EMA SmPC].

Condition-Based and Age Restrictions

Fareston is not indicated for use in the Pediatric population, as safety and efficacy have not been established [FDA Label]. The medicine must not be used during Pregnancy or Lactation [EMA SmPC].

Regulatory cautions apply to several patient groups, including those with a history of thromboembolic disorders (where use is generally not recommended) and those with liver impairment (where caution is advised) [FDA Label]. Before treatment begins, any necessary correction of low potassium or magnesium levels must occur.

Fareston (toremifene) has documented interactions with several categories of medicinal products, primarily due to its metabolic pathway and its effect on heart rhythm.

Clinically Significant Interactions

Interacting Product Category	Rationale and Constraint
Drugs that prolong the QT interval (e.g., certain antiarrhythmics like quinidine, amiodarone, and sotalol, or neuroleptics)	Avoid co-administration due to the additive risk of QTc interval prolongation, which can lead to serious ventricular arrhythmias, including Torsade de pointes. Patients should be screened for risk factors.
Warfarin-type anticoagulants	Avoid concomitant use as anti-estrogens are known to increase the risk of bleeding time. Careful monitoring is required if avoidance is not possible.

Metabolism-Related Interactions

Fareston is principally metabolized by the liver enzyme CYP3A4. Therefore, medicines that affect this enzyme system can alter the concentration of Fareston in the body:

• Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): Co-administration should be avoided as it can significantly increase Fareston exposure.
• Strong CYP3A4 Inducers (e.g., phenobarbital, phenytoin, carbamazepine, apalutamide): Co-administration should be avoided as it may significantly decrease Fareston exposure. If co-administration is necessary, an increase in the Fareston dose may be considered with close monitoring.

Additionally, drugs that decrease renal calcium excretion, such as thiazide diuretics, require caution and monitoring, particularly in patients with bone metastases, due to a potentially increased risk of hypercalcaemia.

Fareston (toremifene) functions as a selective estrogen receptor modulator (SERM). Its primary biological target is the nuclear Estrogen Receptor (ER), specifically Estrogen Receptor Alpha (ERalpha). Toremifene acts as a mixed estrogen agonist/antagonist, exhibiting tissue-specific interaction types.

In mammary tissue, toremifene and its active N-demethylated metabolite operate as antagonists, competitively binding to the ER and blocking the proliferative actions of endogenous estradiol. This receptor binding prevents the ER from inducing transcription of target genes, inhibiting the downstream cellular signaling pathways that govern proliferation.

Conversely, in other tissues, such as bone and the cardiovascular system, toremifene displays partial agonist activity. It interacts with the ER to modulate gene expression, leading to systemic physiological consequences including modified lipid profiles and altered bone mineral density. Toremifene also influences the somatotropic axis by decreasing the circulating concentration of Insulin-like Growth Factor 1 (IGF-I) and increasing Sex Hormone-Binding Globulin (SHBG) levels via hepatic modulation.

Official Dosing and Administration Principles

Fareston (toremifene citrate) is administered as a single 60 mg tablet taken orally once daily. This regimen represents the standard dose for use in the approved population. Higher daily dosages, such as 200 mg or 240 mg, are generally not recommended for treatment as they are associated with greater toxicity without providing additional benefit.

---

Administration and Scheduling

Instruction	Principle of Use
Route of Administration	Oral administration is the only approved method.
Frequency	Administered once daily (60 mg per day).
Timing Relative to Meals	The tablet may be taken with or without food.
Course Duration	Therapy is intended to be continued for an extended period until there is observable progression of the underlying disease.
Missed Dose	If a scheduled daily dose is missed, it should be taken as soon as possible, but if it is near the time for the next scheduled dose, the missed dose should be skipped to prevent doubling the intake.

---

Special Population Rules

• Renal Impairment: No dose adjustment is required in patients with renal insufficiency.
• Hepatic Impairment: The medication should be used with caution, as a dosage reduction may be necessary for patients with liver impairment.
• Geriatric Patients: No general dosage adjustments are typically required for elderly patients, although caution is advised in patients with underlying liver problems.

These established protocols define a standardized, continuous daily regimen that is largely independent of food intake, with specific rules to guide modifications only for patients with hepatic impairment.

Research Evidence / Overview of Studies for Fareston

This section summarizes the official research findings concerning the clinical evaluation of Fareston (Toremifene), focusing on the design and observed patterns of the clinical trials and scientific literature. The text avoids clinical recommendations, dosing advice, or safety details.

Evidence for Use in Metastatic Breast Cancer (Core Indication)

Research into the use of Fareston for advanced cancer is based on multiple large-scale Randomized Controlled Trials (RCTs) that involved postmenopausal women whose cancer was hormone receptor-positive or had an unknown receptor status. These studies were generally designed to observe and measure how Fareston compared to Tamoxifen, the established standard antiestrogen therapy at the time.

Researchers monitored long-term measures of disease progression, including Time to Progression (TTP) and Overall Survival (OS). Pooled data from multiple trials indicated that the observed measurements for TTP and OS were reported as showing no significant statistical difference when compared to the established therapy. Higher doses of the research agent (e.g., 240 mg daily) were explored in some trials, but the reported outcomes did not show a consistent statistical advantage over the standard 60 mg dose studied.

Research Context: Studies in Early-Stage Disease

Research has also explored the use of Fareston as a follow-up treatment (adjuvant therapy) for women with earlier-stage, hormone receptor-positive cancer. Large-scale RCTs were conducted, with some observation periods extending beyond five years. These studies primarily focused on long-term recurrence measures, such as Disease-Free Survival (DFS) and Overall Survival. The findings reported that the measured outcomes for DFS and OS were not statistically different across the comparison groups, which helps contribute to the broader evidence landscape for this class of medicine.

Research Gaps and What Remains Uncertain

Limitations and areas of uncertainty remain in the research: Data are still insufficient to characterize the research agent's activity in patients whose cancer is confirmed to be estrogen receptor-negative ( ER-) due to small patient numbers in primary trials. Furthermore, some research investigating use after other hormonal therapies involved a higher dose (120 mg daily) than the standard dose studied for first-line metastatic treatment (60 mg daily). Findings from studies using this high dose are limited to the specific dose studied, which differs from the standard regimen.

Key Studies & References

1. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93

Common questions about Fareston (FAQ)

---

Q: Does Fareston cause weight gain?

Official reports from clinical trials and post-marketing experience indicate that weight gain is a reported adverse reaction. However, it is noted to occur less frequently than some of the other more common side effects listed in the product information.

---

Q: Can Fareston affect vision or eyes?

Yes, regulatory documents report that ocular abnormalities are a possible effect. Common eye-related adverse reactions can include cataracts, dry eyes, and abnormal visual fields. Rare but serious effects such as sudden vision loss have also been reported in official product information.

---

Q: How is Fareston different from Tamoxifen?

Fareston (Toremifene) and Tamoxifen are both classified as Selective Estrogen Receptor Modulators (SERMs) and are chemically related. Studies that compared them have generally reported that the measured outcomes for Time to Progression and Overall Survival show no statistically significant difference between the two medicines.

---

Q: Do hot flashes from Fareston ever go away?

According to official product information, adverse reactions such as hot flashes are considered antiestrogenic effects that typically occur when treatment is first initiated. The regulatory texts note this as a common side effect experienced during the beginning of the treatment period.

---

Q: Are there any long-term side effects associated with Fareston use?

Official documents highlight that the medicine is associated with serious long-term risks. These risks include the development of Endometrial Carcinoma (a type of uterine cancer) and hyperplasia, and an increased risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism.

---

Q: What kind of foods or drinks should be avoided while taking Fareston?

Regulatory warnings indicate that consuming grapefruit or grapefruit juice is advised against while taking this medicine. Grapefruit can potentially increase the concentration of the drug in the blood, which could raise the risk of serious side effects, including a dangerous change in heart rhythm.

---

Q: Can Fareston interact with herbal supplements?

Yes, the official product information includes a specific interaction warning for the herbal product St. John's wort. Because this supplement is known to affect certain enzymes, it may decrease the level of the drug in the body, potentially reducing its effectiveness.

---

Q: Are there specific vitamins or minerals that Fareston can affect?

Official warnings indicate that Fareston may affect certain mineral levels. The medicine may increase the risk of high calcium levels (hypercalcemia), especially in patients with bone metastases. Additionally, regulatory texts note that low blood levels of potassium and magnesium are conditions that require correction before treatment initiation due to potential heart risks.

---

Q: Does Fareston interact with blood pressure medication?

Official documents state that caution is advised when Fareston is used alongside certain blood pressure medications, particularly thiazide diuretics. This is because using them together may potentially increase the risk of hypercalcemia (high calcium levels) in some patients.

---

Q: Why is Fareston taken once a day?

The once-daily dosing regimen is supported by the drug’s pharmacological properties. Official pharmacokinetic information indicates that the active compound, Toremifene, has a long elimination half-life, meaning it stays in the body for an extended period, approximately five to seven days.

---

Q: Is Fareston safe for patients with liver issues?

Official product information states that the drug should be used with caution in patients with liver impairment, and a dosage reduction may be necessary in some cases. Severe hepatic (liver) failure is listed as a contraindication, meaning the medicine must not be used in that situation.

---

Q: How does the drug Fareston affect estrogen levels?

Fareston is a Selective Estrogen Receptor Modulator (SERM). Its main action is to act as an antagonist, or blocker, by competitively binding to estrogen receptors in breast tissue. This action blocks the effect of the natural estrogen hormone, rather than primarily working by lowering the body’s overall estrogen production.

---

Q: What is the purpose of the laboratory tests often done while taking Fareston?

Monitoring is required to check for potential serious effects of the medication. Tests are used to check the health of the liver, look for high calcium levels, and ensure that potassium and magnesium levels are normal, which is important for heart safety.

---

Q: Why is regular follow-up important while using Fareston?

Official documentation describes the importance of regular follow-up to monitor for potential serious adverse reactions. This monitoring typically includes checking for changes in the uterus, signs of blood clots, and potential changes in liver function and electrolyte levels.

---

Q: What is the half-life of Fareston?

According to official pharmacokinetics data, the reported elimination half-life of the parent compound (Toremifene) is approximately five to seven days. The half-life describes how long it takes for half of the drug to be eliminated from the body.

---

Q: Are there specific official warnings about using Fareston with grapefruit?

Yes, official warnings state that grapefruit and grapefruit juice are substances that should be avoided. Grapefruit can increase the drug concentration in the body and raise the risk of QTc prolongation, which is a serious heart rhythm issue.

---

Q: Is Fareston considered a chemotherapy drug?

Fareston is classified as a Selective Estrogen Receptor Modulator (SERM) and an Antiestrogen. This places it in the class of hormonal therapies, which function differently from traditional cytotoxic chemotherapy, which works by killing rapidly dividing cells.

Storage and Disposal of Fareston (toremifene citrate)

Storage Conditions

Fareston tablets must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C), with excursions permitted to 86 F (30 C). The medicine should be kept away from excessive heat, moisture, direct light, and must be protected from freezing. To maintain product stability, store the tablets in a closed, original container.

Child-Safety Storage

It is mandatory to store this prescription medicine out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Fareston, along with any related waste material, must be disposed of in accordance with local requirements. The medicine must not be disposed of via wastewater or household trash; instead, local collection schemes should be used.